P1.03-037 A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer

Report from the WCLC 2017 Congress, Yokohama, 15th–18th October, 2017

“…Likewise, in a retrospective Korean realworld analysis of 165 patients, first-line afatinib showed similar or even better PFS and OS outcomes compared with the clinical trials [10]. Median PFS was 19.1 months, and median OS had not been reached.…”

“…Osimertinib has shown favourable results as second-line treatment after failure of first-generation or second-generation EGFR TKI therapy in the AURA3 study, but only 7 % of patients included in this trial had received first-line afatinib [10]. At the same time, emerging data suggest favourable clinical outcomes in patients who are prescribed the sequence of afatinib followed by osimertinib.…”

“…Kang et al evaluated the potential effect of primary tumour resection and an aggressive local consolidative therapy on 3-year OS and PFS in patients with metastatic OS and progression-free survival (PFS) [10]. Moreover, the objectives included the assessment of surgical outcomes in the treatment of patients with metastatic NSCLC and the identification of clinical factors that predict OS and PFS, in order to improve patient selection for surgery.…”

“…The primary analysis has revealed significant superiority of pembrolizumab over chemotherapy with respect to PFS (HR, 0.50) and OS (HR, 0.60), but median OS in the pembrolizumab arm had not been reached at that time [10].…”

“…A prospective, multiinstitutional phase II study evaluated the feasibility of combination chemotherapy with docetaxel and nedaplatin in the adjuvant treatment of 34 patients with NSCLC stage IB-IIIA, who had undergone radical surgery including lobectomy and lymph node dissection [10]. On day 1 of 4 cycles, docetaxel and nedaplatin were administered at 60 mg/ m² and 80 mg/m², respectively.…”